VISN

CommScope Holding Company, Inc.
NASDAQTECHNOLOGYCOMMUNICATION EQUIPMENT

Key Statistics

Market Cap
$2.69B
P/E Ratio
17.54
EPS
$0.68
Beta
1.93
52W High
$13.22
52W Low
$3.48
50-Day MA
$12.43
200-Day MA
$16.42
Dividend Yield
0.00%
Profit Margin
347.70%
Forward P/E
3.72
PEG Ratio
2.94

About CommScope Holding Company, Inc.

Gyroscope Therapeutics Holdings plc, a clinical-stage gene therapy company, develops gene therapy products to treat patients with eye diseases. The company is headquartered in Stevenage, the United Kingdom.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$2.02B
Gross Profit (TTM)$992.00M
EBITDA$378.50M
Operating Margin7.06%
Return on Equity13.10%
Return on Assets1.36%
Revenue/Share (TTM)$9.09
Book Value$20.37
Price-to-Book0.60
Price-to-Sales (TTM)1.33
EV/Revenue0.124
EV/EBITDA0.79
Quarterly Earnings Growth (YoY)704.00%
Quarterly Revenue Growth (YoY)21.60%
Shares Outstanding$225.57M
Float$214.88M
% Insiders3.25%
% Institutions97.49%

Historical Volatility

HV 10-Day
HV 20-Day
HV 30-Day
HV 60-Day
HV Rank

Analyst Ratings

Consensus ($17.33 target)
1
Buy
3
Hold

Latest News

Belden Completes Acquisition of RUCKUS Networks

ST. LOUIS--(BUSINESS WIRE)--Belden Inc. (NYSE: BDC) (“Belden” or the “Company”), a leading global supplier of specialty networking solutions, today announced that it has completed its acquisition of RUCKUS Networks (“RUCKUS”), a global provider of intelligent network solutions, from Vistance Networks (Nasdaq: VISN). RUCKUS' leading enterprise networking portfolio, including industry-leading Wi-Fi, enterprise switching capabilities and AI driven network management platforms, make Belden a preemi.

Business Wire7/1/2026Neutral

More TECHNOLOGY Stocks

Data last updated: 7/9/2026